[이코노믹리뷰=황진중 기자] A global forum will be prepared to discuss strategies for creating K-blockbusters through open innovation.
The Korea Pharmaceutical Bio Association announced on the 22nd that it will hold the K-Blockbuster Global Forum online at 9:30 am on the 30th.
The government has selected pharmaceutical bio as the big 3 industry that will drive the future national economy along with future vehicles and system semiconductors, and has announced a plan to create a mega fund for the development of a global blockbuster.
The creation of K blockbuster is regarded as a key task for the pharmaceutical bio industry to establish itself as the big three industry in the future. This is because the birth of a blockbuster through the discovery of candidate substances, global phase 2 and 3 clinical trials, and acquisition of marketing licenses before new drug development signifies the creation of enormous local wealth and entry into the global Big Pharma.
The Pharmaceutical Bio Association plans to invite world-renowned scholars and experts to this forum to present’how a global blockbuster is made’ and’what is a K-blockbuster development model’. It is expected that the urgency of creating a mega fund necessary for the global phase 2 and 3 of K blockbuster development will also be discussed.
On this day, the forum will open with a keynote lecture by Professor Si-young Song of Yonsei University College of Medicine,’Why is K-Blockbuster Now?’ Afterwards, in the first part of the theme of’How a Global Blockbuster Is Made’ ▲ Milner Research Institute and Academic Business Paradigm (Tony Kujarize, Director of Milner Research Institute, Cambridge Medical School, UK) ▲ Trends and Prospects for New Blockbuster Drug Development (Deborah Kobeka Evaluate CEO) ▲ Topics such as success factors and examples through the partnership of Global Big Pharma (Merck) (Mathias Mullenbeck, General Manager of Merck Global Business Development Division and General Manager of Access to Innovation, Belgit Lightmeier Merck’s Asia Pacific Headquarters) will be presented.
Part 2 of’K Blockbuster, How We Should Do’ is ▲Organizational and human capabilities necessary for a global leap forward of Korean companies (Soohee Park, Chairman of Korean Pharmaceutical Association of Korea/Novatis USA) ▲Challenges and strategies for completing the 3rd global phase, the entire cycle (Bang Young-ju, CEO Bang & Ok Consulting) ▲K-blockbuster development model (Kyung-Hwa Heo, CEO of Korea Innovative Medicines Consortium) will proceed in order
Chairman Hee-mok Won said, “Now the domestic pharmaceutical bio industry is also at the point of joining the ranks of the world’s big pharma through global open innovation,” he said. “For this, we must create a successful case of completing the entire blockbuster process.”